Optimal molecular crowding accelerates group II intron folding and maximizes catalysis

Unlike in vivo conditions, group II intron ribozymes are known to require high magnesium(II) concentrations ([Mg2+]) and high temperatures (42 °C) for folding and catalysis in vitro. A possible explanation for this difference is the highly crowded cellular environment, which can be mimicked in vitro...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 115; no. 47; pp. 11917 - 11922
Main Authors Paudel, Bishnu P., Fiorini, Erica, Börner, Richard, Sigel, Roland K. O., Rueda, David S.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 20.11.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Unlike in vivo conditions, group II intron ribozymes are known to require high magnesium(II) concentrations ([Mg2+]) and high temperatures (42 °C) for folding and catalysis in vitro. A possible explanation for this difference is the highly crowded cellular environment, which can be mimicked in vitro by macromolecular crowding agents. Here, we combined bulk activity assays and single-molecule Förster Resonance Energy Transfer (smFRET) to study the influence of polyethylene glycol (PEG) on catalysis and folding of the ribozyme. Our activity studies reveal that PEG reduces the [Mg2+] required, and we found an “optimum” [PEG] that yields maximum activity. smFRET experiments show that the most compact state population, the putative active state, increases with increasing [PEG]. Dynamic transitions between folded states also increase. Therefore, this study shows that optimal molecular crowding concentrations help the ribozyme not only to reach the native fold but also to increase its in vitro activity to approach that in physiological conditions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
1B.P.P., E.F., and R.B. contributed equally to this work.
Edited by Joseph D. Puglisi, Stanford University School of Medicine, Stanford, CA, and approved October 5, 2018 (received for review May 21, 2018)
Author contributions: B.P.P., E.F., R.B., R.K.O.S., and D.S.R. designed research; B.P.P., E.F., and R.B. performed research; B.P.P., E.F., R.B., R.K.O.S., and D.S.R. analyzed data; and B.P.P., E.F., R.B., R.K.O.S., and D.S.R. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1806685115